| 04.11 12:01 | dpa-AFX: Illumina Q3 24 Earnings Conference Call At 4:30 PM ET |
| 03.10 23:50 | dpa-AFX: *ILLUMINA : CHARLES DADSWELL TO STEP DOWN AS GENERAL COUNSEL AND SECRETARY |
| 03.09 12:48 | EuGH kippt EU-Übernahmeverbot für Illumina und Grail |
| 03.09 11:31 | dpa-AFX: Illumina Not To Pay EUR 432 Mln EU Fine Over Grail Deal After Favorable European Court Verdict |
| 03.09 10:10 | dpa-AFX: *ILLUMINA WELCOMES JUDGMENT RULING THAT EC DID NOT HAVE JURISDICTION OVER ILLUMINA'S ACQUISITION OF GRAIL |
| 27.08 15:41 | dpa-AFX: Illumina's Cancer Biomarker Test With Two Companion Diagnostics Gets FDA Approval |
| 27.08 15:19 | dpa-AFX: *FDA APPROVES ILLUMINA CANCER BIOMARKER TEST WITH TWO COMPANION DIAGNOSTICS FOR TARGETED THERAPIES |
| 13.08 17:58 | dpa-AFX: Illumina Plans To Boost Revenue Growth Into High Single Digits By 2027; Stock Down |
| 13.08 17:03 | dpa-AFX: *ILLUMINA AIMS TO DRIVE DOUBLE DIGIT TO TEENS NON-GAAP EPS GROWTH FROM 2025 TO 2027 |
| 13.08 17:02 | dpa-AFX: *ILLUMINA EXPECTS STRATEGY TO ENABLE COMPANY TO ACCELERATE REVENUE GROWTH TO HIGH SINGLE DIGITS BY 2027 |
| 06.08 22:13 | dpa-AFX: Illumina Inc. Q2 Earnings Summary |
| 06.08 22:13 | dpa-AFX: *ILLUMINA Q2 REVENUE $1.11 BLN VS. $1.18 BLN LAST YEAR |
| 06.08 22:13 | dpa-AFX: *ILLUMINA Q2 NET LOSS $1.99 BLN VS. LOSS $234 MLN PRIOR YEAR |
| 06.08 22:13 | dpa-AFX: *ILLUMINA Q2 LOSS/SHARE $12.48 VS. LOSS $1.48 YEAR AGO |
| 06.08 21:01 | dpa-AFX: Illumina Q2 24 Earnings Conference Call At 4:30 PM ET |
| 11.07 06:20 | ÜBERBLICK/Anstehende Indexänderungen |
| 09.07 22:23 | dpa-AFX: Illumina Buys Fluent BioSciences |
| 09.07 22:08 | dpa-AFX: *ILLUMINA ACQUIRES FLUENT BIOSCIENCES |
| 24.06 22:44 | dpa-AFX: Illumina Completes Spin-off Of GRAIL |
| 24.06 22:06 | dpa-AFX: *ILLUMINA COMPLETES DIVESTITURE OF GRAIL |
|
|
